New hope for myeloma drug

British scientists may have found a drug that could tackle the bone marrow cancer myeloma without causing serious side-effects, it was announced last night.

So far the new drug, DTP3, has been used to destroy myeloma cells in laboratory conditions, involving human cells and mice.

But the researchers say there is no sign of the toxic side-effects that most cancer drugs have.

They revealed their findings in the journal Cancer Cell.

Doctors now hope to begin testing the drug on patients early next year with backing from the UK Medical Research Council.

The drug was discovered as scientists sought to overcome problems with drugs that have been developed to target a protein called NF-kB – nuclear factor kappa B – which becomes overactive in many kinds of cancer.

Their work centred on patients with multiple myeloma as they went "downstream" to find genes involved in NF-kB.

Researcher Professor Guido Franzoso, from Imperial College, London, UK, said the drug might work for some other cancers.

He said: "Lab studies suggest that DTP3 could have therapeutic benefit for patients with multiple myeloma and potentially several other types of cancer, but we will need to confirm this in our clinical trials, the first of which will start next year.

“We had known for many years that NF-kB is very important for cancer cells, but because it is also needed by healthy cells, we did not know how to block it specifically."

Tornatore et al. Cancer-selective targeting of the NF-kB survival pathway with GADD45ß/MKK7 inhibitors. Cancer Cell 13 October 2014.

, ,

Leave a Reply

Your email address will not be published. Required fields are marked *

Search

Categories

Monthly Posts

Our Clients

BSH
Practice Index